Under the terms of the agreement, Alfacell has granted BL&H exclusive rights in the defined territory for the marketing, sales and distribution of Onconase (ranpirnase). Alfacell has received an upfront fee of $100,000 and is eligible for milestone payments based on the achievement of certain regulatory approvals and net sales levels. Alfacell will also receive 50% of all net sales in the territory.
In addition, Alfacell will manufacture and supply the product to BL&H, while BL&H will be responsible for all activities and costs related to regulatory filings and commercial activities in the territory.